OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO )
Andreas Pinter, L. Puig, Knut Schäkel, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2087-2100
Open Access | Times Cited: 27
Andreas Pinter, L. Puig, Knut Schäkel, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2087-2100
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 19
Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 19
Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
Adam Reich, Catherine Reed, Christopher Schuster, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Adam Reich, Catherine Reed, Christopher Schuster, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study
Ricardo Ruíz‐Villaverde, Pedro J. Ezomo-Gervilla, José Molina-Espinosa, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 833-833
Open Access
Ricardo Ruíz‐Villaverde, Pedro J. Ezomo-Gervilla, José Molina-Espinosa, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 833-833
Open Access
Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance
Hideshi Torii, Akimichi Morita, Chie Yamamoto, et al.
The Journal of Dermatology (2025)
Open Access
Hideshi Torii, Akimichi Morita, Chie Yamamoto, et al.
The Journal of Dermatology (2025)
Open Access
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
Elisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1327-1335
Open Access | Times Cited: 3
Elisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1327-1335
Open Access | Times Cited: 3
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
Charles Lynde, Elisabeth Riedl, Julia‐Tatjana Maul, et al.
Advances in Therapy (2022) Vol. 40, Iss. 3, pp. 869-886
Open Access | Times Cited: 15
Charles Lynde, Elisabeth Riedl, Julia‐Tatjana Maul, et al.
Advances in Therapy (2022) Vol. 40, Iss. 3, pp. 869-886
Open Access | Times Cited: 15
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
Andreas Pinter, Antonio Costanzo, Sanjay Khattri, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 6, pp. 1479-1493
Open Access | Times Cited: 8
Andreas Pinter, Antonio Costanzo, Sanjay Khattri, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 6, pp. 1479-1493
Open Access | Times Cited: 8
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
Dennis McGonagle, Arthur Kavanaugh, Iain B. McInnes, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 3115-3123
Open Access | Times Cited: 2
Dennis McGonagle, Arthur Kavanaugh, Iain B. McInnes, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 3115-3123
Open Access | Times Cited: 2
Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
Kossara Drenovska, Elia Valeva, Martin Shahid, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Kossara Drenovska, Elia Valeva, Martin Shahid, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks
Adam Reich, Andreas Pinter, Julia‐Tatjana Maul, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1825-1840
Open Access | Times Cited: 6
Adam Reich, Andreas Pinter, Julia‐Tatjana Maul, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1825-1840
Open Access | Times Cited: 6
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
Rieke Alten, Gerd R Burmester, Marco Matucci‐Cerinic, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1575-1595
Open Access | Times Cited: 6
Rieke Alten, Gerd R Burmester, Marco Matucci‐Cerinic, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1575-1595
Open Access | Times Cited: 6
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 4
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 4
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
April W. Armstrong, Álvaro González‐Cantero, Saakshi Khattri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 933-952
Open Access | Times Cited: 1
April W. Armstrong, Álvaro González‐Cantero, Saakshi Khattri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 933-952
Open Access | Times Cited: 1
Psoriatic nail complex: thick as thieves
J. Pinto-Tasende, Rubén Queiró
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 2903-2904
Open Access | Times Cited: 1
J. Pinto-Tasende, Rubén Queiró
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 2903-2904
Open Access | Times Cited: 1
T cell responses in immune-mediated IgA nephropathy
Shimin Xie, Meng‐Ying Sun, Xiaohan Zhang, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 3, pp. 523-535
Closed Access | Times Cited: 1
Shimin Xie, Meng‐Ying Sun, Xiaohan Zhang, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 3, pp. 523-535
Closed Access | Times Cited: 1
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
April W. Armstrong, Elisabeth Riedl, Patrick M. Brunner, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40556-adv40556
Open Access | Times Cited: 1
April W. Armstrong, Elisabeth Riedl, Patrick M. Brunner, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40556-adv40556
Open Access | Times Cited: 1
Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 21, Iss. 12, pp. 1513-1523
Open Access | Times Cited: 2
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 21, Iss. 12, pp. 1513-1523
Open Access | Times Cited: 2
Biologika in der dermatologischen Praxis – eine 20-jährige Geschichte
Sigbert Jahn, Evangelia Diamanti, Christine Wagner, et al.
Aktuelle Dermatologie (2024) Vol. 50, Iss. 06, pp. 281-290
Closed Access
Sigbert Jahn, Evangelia Diamanti, Christine Wagner, et al.
Aktuelle Dermatologie (2024) Vol. 50, Iss. 06, pp. 281-290
Closed Access
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1615-1631
Open Access
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1615-1631
Open Access
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations
Giuseppe Lopalco, Andrea Cito, Vincenzo Venerito, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 835-853
Closed Access
Giuseppe Lopalco, Andrea Cito, Vincenzo Venerito, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 835-853
Closed Access
Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients
Wolf‐Henning Boehncke, Adam Reich, Sonja Ständer, et al.
JEADV Clinical Practice (2024) Vol. 3, Iss. 5, pp. 1509-1517
Open Access
Wolf‐Henning Boehncke, Adam Reich, Sonja Ständer, et al.
JEADV Clinical Practice (2024) Vol. 3, Iss. 5, pp. 1509-1517
Open Access
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
Saakshi Khattri, Álvaro González‐Cantero, Burhan Engın, et al.
Advances in Therapy (2024)
Open Access
Saakshi Khattri, Álvaro González‐Cantero, Burhan Engın, et al.
Advances in Therapy (2024)
Open Access
Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: The First Septennium
Elena Carmona‐Rocha, L. Puig
Immunotherapy (2023) Vol. 15, Iss. 15, pp. 1209-1225
Closed Access | Times Cited: 1
Elena Carmona‐Rocha, L. Puig
Immunotherapy (2023) Vol. 15, Iss. 15, pp. 1209-1225
Closed Access | Times Cited: 1
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Andrew Blauvelt, Alyssa Garrelts, William N. Malatestinic, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2911-2916
Open Access | Times Cited: 1
Andrew Blauvelt, Alyssa Garrelts, William N. Malatestinic, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2911-2916
Open Access | Times Cited: 1
